Related Experiment Video
Updated: Jun 13, 2025
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
Immune checkpoint inhibitor-induced cholangitis-a three-case series
Simon Gray1,2, Nuria Santamaria3, Anna Olsson-Brown1,2
1Department of Medical Oncology, Clatterbridge Cancer Centre NHS Foundation Trust, L7 8YA Liverpool, UK.
Immune checkpoint inhibitors (ICIs) can cause rare but severe cholangitis. Early diagnosis and management are crucial for this serious toxicity, often presenting with distinct radiological findings.
Area of Science:
- Oncology
- Immunology
- Gastroenterology
Background:
- Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy for solid tumors.
- However, ICIs can trigger immune-related adverse events affecting various organs.
Observation:
- ICI-induced cholangitis is a rare but significant toxicity.
- This condition presents diagnostic and management challenges.
Findings:
- Case studies reveal characteristic radiological findings, including intrahepatic duct abnormalities.
- Progressive intrahepatic duct dilatation and pericholecystic haziness suggest sclerosing cholangitis and inflammation.
Implications:
- Recognizing these radiological signs is vital for timely diagnosis of ICI-induced cholangitis.
- Understanding this rare toxicity aids in optimizing patient management and outcomes.
More Related Videos
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
